Excessive proliferation matched by excessive apoptosis in myelodysplastic syndromes: The cause-effect relationship

被引:37
作者
Raza, A
Alvi, S
Borok, RZ
Span, L
Parcharidou, A
Alston, D
Rifkin, S
Robin, E
Shah, R
Gregory, SA
机构
[1] Rush Cancer Institute, Rush-Presbyt.-St. Luke's Med. Center, Chicago, IL
[2] Department of Pathology, Rush-Presbyt.-St. Luke's Med. Center, Chicago, IL
[3] 2nd Department of Internal Medicine, University of Athens, Hospital Evangelismos, Athens
[4] LaPorte Cancer Treatment Center, LaPorte, IN
[5] Northwest Community Hospital, Arlington Heights, IL
[6] Ingall's Memorial Hospital, Harvey, IL
[7] Lake Forest Hospital, Deerfield, IL
关键词
apoptosis; proliferation; signal antonymy; myelodysplastic syndromes; tumor necrosis factor alpha;
D O I
10.3109/10428199709068277
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
The paradox of pancytopenia despite cellular bone marrows (BM) was investigated in 120 patients with myelodysplastic syndromes (MDS). Detailed cell cycle kinetics were examined following in vivo infusions of iodo-and/or bromodeoxyuridine (IUdR/BrdU), while the incidence of apoptosis was measured by in situ end labeling (ISEL) of fragmented DNA. Results showed that MDS are highly proliferative disorders with an equally high incidence of apoptotic intramedullary cell death accounting for the paradox of cellularity/cytopenia. By double-labeling BM biopsy sections for ISEL/BrdU we found the peculiar situation of ''signal antonymy'' where S-phase cells were frequently apoptotic, a phenomenon so far only seen in MDS biopsies. The cause-effect relationship of this excessive proliferation/apoptosis is discussed at length.
引用
收藏
页码:111 / 118
页数:8
相关论文
共 26 条
  • [1] ASANO H, 1994, BLOOD, V84, P588
  • [2] PROPOSALS FOR THE CLASSIFICATION OF THE MYELODYSPLASTIC SYNDROMES
    BENNETT, JM
    CATOVSKY, D
    DANIEL, MT
    FLANDRIN, G
    GALTON, DAG
    GRALNICK, HR
    SULTAN, C
    [J]. BRITISH JOURNAL OF HAEMATOLOGY, 1982, 51 (02) : 189 - 199
  • [3] POLYCLONAL PRIMITIVE HEMATOPOIETIC PROGENITORS CAN BE DETECTED IN MOBILIZED PERIPHERAL-BLOOD FROM PATIENTS WITH HIGH-RISK MYELODYSPLASTIC SYNDROMES
    DELFORGE, M
    DEMUYNCK, H
    VANDENBERGHE, P
    VERHOEF, G
    ZACHEE, P
    VANDUPPEN, V
    MARIJNEN, P
    VANDENBERGHE, H
    BOOGAERTS, MA
    [J]. BLOOD, 1995, 86 (10) : 3660 - 3667
  • [4] TREATMENT OF MYELODYSPLASTIC SYNDROMES WITH HEMATOPOIETIC GROWTH-FACTORS
    GANSER, A
    HOELZER, D
    [J]. HEMATOLOGY-ONCOLOGY CLINICS OF NORTH AMERICA, 1992, 6 (03) : 633 - 653
  • [5] GREENBERG PL, 1992, SEMIN ONCOL, V19, P106
  • [6] Hibner U, 1994, Cell Death Differ, V1, P33
  • [7] JANSSEN JWG, 1989, BLOOD, V73, P248
  • [8] NOVEL IN-SITU DOUBLE-LABELING FOR SIMULTANEOUS DETECTION OF PROLIFERATION AND APOPTOSIS
    MUNDLE, S
    IFTIKHAR, A
    SHETTY, V
    DAMERON, S
    WRIGHTQUINONES, V
    MARCUS, B
    LOEW, J
    GREGORY, S
    RAZA, A
    [J]. JOURNAL OF HISTOCHEMISTRY & CYTOCHEMISTRY, 1994, 42 (12) : 1533 - 1537
  • [9] MUNDLE SD, 1996, P AN M AM SOC CLIN, V15, P89
  • [10] NEGRIN RS, 1993, BLOOD, V82, P737